Mike Stella

INCELL Pioneering the World’s First Effective Cell Therapy for #ALS - https://lnkd.in/g64wfbkS San Antonio, Texas, July 25, 2024 – ALS, or amyotrophic lateral sclerosis, is defined by the ALS Association (als.org) as a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS symptoms vary and patients may lose the ability to speak, eat, move and breathe. There is no cure. The Mayo Clinic reports (mayoclinic.org) that no treatments can reverse ALS damage, but they may slow the progression of disease symptoms or help prevent complications. INCELL is committed to tackling innovative ALS therapy. INCELL Corporation’s Chief Science Officer and ALS Project Manager, Dr. Mary Pat Moyer says “Our INCELL team brought together our 31 years’ experience and leveraged our deep scientific, medical, and clinical knowledge of human cells and biomanufacturing. The complexity of the ALS disease, its self-destructive autoimmunity, and its damage to multiple body functions, led us to think that combinations of cell therapies might help ALS patients. We thought that bringing together INCELL’s banked stem cells, which can stimulate neural and tissue repair, combined with a patient’s regulatory immune cells might reduce inflammation, restore immune system balance, and lead to patient improvements. We were right! INCELL plans to expand cell therapies to more patients in more clinical trials while providing a business model for at-home and close-to-home care, with tools for at-home monitoring, while considering the needs of individual patients and their caregivers.” As stated by Dr. Peter Edenhoffer, INCELL’s Clinical Investigator for ALS cell therapy studies and a practicing neurologist: “I had hoped to learn important information from doing this clinical study, but my experience made me skeptical about outcomes, since no ALS patient’s clinical condition has been improved by any ALS therapy. Now, we have seen many significant, quantified ALS patient improvements after these effective cell therapies. My enthusiasm is now very high for using these unique cell therapies to treat more patients with ALS, other neural diseases, and trauma.” Read more at: https://lnkd.in/g64wfbkS #neurodegenerative #celltherapy #advancedtherapy

8

Exciting news! Celestial AI has acquired Rockley Photonics' optical I/O portfolio, enhancing its capabilities in high-performance computing and AI. This strategic move aims to boost data transfer speeds and energy efficiency, positioning Celestial AI as a leader in the future of computing. Stay tuned! #Innovation #Photonics #AI

6

1 Comment

Interested in the latest developments at the FDA's Office of Therapeutic Products (#OTP)? Join a free, public webinar on June 14th featuring Dr. Nicole Verdun, OTP's Super Office Director, and Rachael Anatol, Ph.D., Deputy Super Office Director. What you'll learn: The new "Super Office" structure of the OTP Progress on hiring new staff An overview of the OTP's organization Brought to you by Alliance for Regenerative Medicine. Please use the link in the post below. #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #lifescience #lifesciences #regulatory #structure #biotech #biotechnology #webinar #productupdate #regulatorystructure

12

Cost and speed are critical components in biomanufacturing. See how ÄKTA pilot 600 supports scale-up from process development to GMP clinical scale. Try this ÄKTA system in 3D https://lnkd.in/gkYFvSwu

4

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Read: https://lnkd.in/eJ8KFVF5 #sciencesdelavie #biotechnology #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #revolution #happy

1

To compete in a regulated industry, it is imperative to go digital with a completely 21 CFR Part 11 and EU Annex 11 compliant solution. ACE is leading the market in terms of flexibility, reliability, affordability, support, and compliance for a digital solution.

11

3 Comments

ANOTHER PATENT ISSUED for BIOELECTRIC STIMULATOR https://lnkd.in/g2cCCnkq for organ regeneration including skin and hair, healing including joint health and healthspan extension October 8th, 2014 by the USPTO! https://lnkd.in/g2cCCnkq with 15 new claims including... 3. The method according to claim 1, wherein the target tissue is selected from the group consisting of brain, scalp, eye, ear, skin, tooth, dental gum, tooth root, sub-mucosa, breast, aorta, limb, artery, heart, heart valve, kidney, pancreas, bladder, liver, joint, bone, and any combination thereof.

2